Drugs / Filociclovir
Filociclovir
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02454699 | Nov 2015 → Apr 2017 | cytomegalovirus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT01433835 | Sep 2011 → Aug 2012 | — | Microbiotix, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Filociclovir | “Filociclovir (MBX-400, Cyclopropavir)” PMID 31285228 ↗ Aug 2019 |
| Known as | Cyclopropavir | “Filociclovir (MBX-400, Cyclopropavir)” PMID 31285228 ↗ Aug 2019 |
| Known as | MBX-400 | “Filociclovir (MBX-400, Cyclopropavir)” PMID 31285228 ↗ Aug 2019 |
| Known as | ZSM-162 | ChEMBL registry synonym — accepted as the source's own label CHEMBL265948 ↗ |
| Known as | ZSM-I 62 | ChEMBL registry synonym — accepted as the source's own label CHEMBL265948 ↗ |
| Action | Inhibit | “MBX-400, has been shown to be a potent inhibitor of viral DNA synthesis” NCT01433835 ↗ |
| Modality | Small molecule | “MBX-400 is a nucleoside analog” NCT01433835 ↗ |